GlassScriptPhysician profile
Paul B Moore
NPI 1285668699
$988.03
in general payments reported to CMS, 2019-2025
15 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $72.48 · 2021: $20.60 · 2022: $121 · 2023: $210 · 2024: $71.86 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $190.48 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Janssen Pharmaceuticals, INC | $178.72 | 2019-2020 | |
| Boston Scientific Corporation | $165.36 | 2021-2025 | Axonics, Lithoclast |
| Novartis Pharmaceuticals Corporation | $89.12 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $72.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $71.65 | 2019-2025 | Camzyos |
| Biotronik INC. | $54.55 | 2022 | |
| Lantheus Medical Imaging, INC. | $36.49 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.74 | 2019 | |
| Akcea Therapeutics, INC. | $27.11 | 2019 | |
| Abiomed | $19.05 | 2023 | Impella |
| Philips North America LLC | $15.22 | 2024 | (Dd1) Duo Hybrid |
| Pfizer INC. | $13.85 | 2019 | |
| Medtronic, INC. | $13.70 | 2022 | |
| Celonova Biosciences, INC. | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.